

Special Issue

Neurodevelopmental Disorders: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editors

DSM-5, introduced in 2013, allowed a renewed appreciation of the longitudinal, whole-life perspective of neurodevelopmental disorders in psychiatry including autism spectrum disorder (ASD) and other communication, speech, and language disorders, attention-deficit/hyperactivity disorder (ADHD), intellectual disability (ID) as well as other specific learning disorders. However, our understanding of the basic aspects of the pathophysiology of these disorders and efficient therapies are still incomplete. The adult population suffering from these disorders is especially widely under researched and does rarely benefit from adequate treatments. With this Special Issue of *Biomedicines*, we aim to present to the readers of the journal the actual state of the art in the understanding of the pathophysiology of neurodevelopmental disorders and their treatments, from birth to the end of life.

Guest Editors

Dr. Nader Perroud

1. Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland

2. TRE Unit, Division of Psychiatric Specialties, Department of Psychiatry, University Hospital of Geneva, Geneva, Switzerland

Dr. Markus Mathaus Kosel

Hôpitaux universitaires de Genève, Geneva, Switzerland

Deadline for manuscript submissions

closed (31 October 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/72976

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).